https://www.selleckchem.com/pr....oducts/elamipretide-
The weight-bearing distribution in the 10 and 10 MSCs groups at 12 weeks after ACLT and in the 10 MSCs group at 6, 8, 10, and 12 weeks after ACLT were significantly higher than those of the control group. A clinically feasible number of MSCs was found to reduce the articular cartilage degeneration and to decrease pain in the PTOA model. Increasing numbers of the cells further protected the articular cartilage against degeneration. A clinically feasible number of MSCs was found to reduce the articular cartilage degeneration
Like
Comment
Share
